资讯
The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...
Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...
FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
Note that some links may require registration or subscription. An Air India passenger plane bound for London with more than ...
2 天
Zacks Investment Research on MSNNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseNovavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...
U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Preventions ...
3 天
Stocktwits on MSNNovavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In ...Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...
The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...
Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果